- Home
- RQI vs HRMY Comparison
RQI vs HRMY Comparison
Compare RQI & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RQI
- HRMY
- Stock Information
- Founded
- RQI 2002
- HRMY 2017
- Country
- RQI United States
- HRMY United States
- Employees
- RQI N/A
- HRMY N/A
- Industry
- RQI Trusts Except Educational Religious and Charitable
- HRMY Biotechnology: Pharmaceutical Preparations
- Sector
- RQI Finance
- HRMY Health Care
- Exchange
- RQI Nasdaq
- HRMY Nasdaq
- Market Cap
- RQI 1.7B
- HRMY 2.0B
- IPO Year
- RQI N/A
- HRMY 2020
- Fundamental
- Price
- RQI $12.30
- HRMY $31.89
- Analyst Decision
- RQI
- HRMY Strong Buy
- Analyst Count
- RQI 0
- HRMY 9
- Target Price
- RQI N/A
- HRMY $54.22
- AVG Volume (30 Days)
- RQI 432.6K
- HRMY 611.9K
- Earning Date
- RQI 01-01-0001
- HRMY 08-05-2025
- Dividend Yield
- RQI 8.20%
- HRMY N/A
- EPS Growth
- RQI N/A
- HRMY 13.13
- EPS
- RQI N/A
- HRMY 2.62
- Revenue
- RQI N/A
- HRMY $744,852,000.00
- Revenue This Year
- RQI N/A
- HRMY $20.10
- Revenue Next Year
- RQI N/A
- HRMY $18.01
- P/E Ratio
- RQI N/A
- HRMY $12.17
- Revenue Growth
- RQI N/A
- HRMY 20.62
- 52 Week Low
- RQI $9.17
- HRMY $26.47
- 52 Week High
- RQI $12.64
- HRMY $41.61
- Technical
- Relative Strength Index (RSI)
- RQI 48.59
- HRMY 36.85
- Support Level
- RQI $12.22
- HRMY $32.39
- Resistance Level
- RQI $12.42
- HRMY $33.42
- Average True Range (ATR)
- RQI 0.14
- HRMY 1.06
- MACD
- RQI -0.02
- HRMY -0.47
- Stochastic Oscillator
- RQI 24.24
- HRMY 6.91
About RQI Cohen & Steers Quality Income Realty Fund Inc
COHEN & STEERS QUALITY INCOME REALTY FUND INC is a diversified, closed-end management investment company. The primary investment objective of the Fund is high current income through investment in real estate securities. Its secondary objective is capital appreciation. The Fund invests at least its total assets in income-producing common stocks and other securities issued by real estate companies, such as real estate investment trusts under normal market conditions.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company's product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.